Pfizer anticipates funding the transaction through a combination of existing cash and new debt and expects the transaction to result in $800 million in annual cost savings by 2018, according to a news release.
In a statement, John Young, group president of Pfizer Global Established Pharmaceutical business, said adding Hospira “has the potential to fundamentally improve the growth trajectory of the Global Established Pharmaceutical business, vault it into a leadership position in the large and growing off-patent sterile injectables marketplace by combining the specialized talent and capabilities of both companies, including enhanced manufacturing, and advance its goal to be among the world’s most preeminent biosimilars providers.”
Hospira CEO F. Michael Ball added, “The Pfizer-Hospira combination is an excellent strategic fit, presenting a unique opportunity to leverage the complementary strengths of our robust portfolios and rich pipelines.”
The definitive merger agreement is expected to close in the second half of this year.
Most articles on transactions and valuation issues:
Tenet says hospital takeover talks in Connecticut are over
Cardinal Hill Rehabilitation Hospital sold to HealthSouth
North Shore-LIJ, Maimonides Medical Center exploring partnership
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.